YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
Jiyeon YunMin Hee HongSeok-Young KimChae-Won ParkSoyoung KimMi Ran YunHan Na KangKyoung-Ho PyoSung Sook LeeJong Sung KohHo-Juhn SongDong Kyun KimYoung-Sung LeeSe-Woong OhSoongyu ChoiHye Ryun KimByoung Chul ChoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Our findings suggest that YH25448 is a promising third-generation EGFR inhibitor, which may be more effective and better tolerated than the currently approved osimertinib.